Drug intelligence / Profile preview

SV-103

Development stage: Preclinical
Lead developer: Kangweizhonghe

Overview

SV-103 is an investigational drug candidate currently in the preclinical stage of development for the treatment of tuberculosis. Developed by Kangweizhonghe Biopharmaceutical, the specific molecular modality and mechanism of action for SV-103 have not been publicly disclosed. The company's broader pipeline in tuberculosis includes advanced biologics such as recombinant fusion proteins, suggesting that SV-103 may be part of a strategic focus on novel therapeutic or preventative interventions for Mycobacterium tuberculosis infections.

Beyond the preview

Go deeper on SV-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SV-103.

Explore the full profile